Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Verification of new technology in new biological drug candidate

Reference number
Coordinator ILYA PHARMA AB
Funding from Vinnova SEK 3 500 000
Project duration October 2017 - July 2018
Status Completed

Purpose and goal

The overall aim with the project is to develop a new biologic medical product to treat large and chronic wounds. The goal is that the new treatment will bring clinical value both to patients with large and chronic wounds and to the health care system. This project is a subproject in a critical phase in the drug development where the technology is validated for safety and efficacy in large animals and healthy volunteers as well as industrialization and scaling of the manufacturing process.

Expected effects and result

The results from this project is in line with what is required in terms of regulations transitioning from a preclinical to clinical phase and in parallel developing the company and starting to plan the case for the finished product and market approval.

Planned approach and implementation

This project has two parts, one for planning, strategy (clinical and commecial), dissemination of results and to build a strong team. The other part concerns the execution of key activities in the drug development project. The SweLife project have progressed according to plan.

External links

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 8 January 2019

Reference number 2017-03573

Page statistics